Sarcoma
8 videos · last 6 months shuffled daily, then older videos newest first
▶
22:39 Sarcoma Exchange 2026: Clinical Trial Basics with Hope Ventricelli of CISCRP
Hope Ventricelli of CISCRP covers the fundamentals — trial phases, informed consent, the protections in place for patients, and what taking part actually involves.
▶
29:14 Sarcoma Exchange 2026: What Makes Sarcoma Clinical Trials Different with Dr. Seth Pollack
Dr. Seth Pollack of Northwestern's Lurie Cancer Center on what makes sarcoma trials different: small patient populations, subtype-specific studies, and a growing role for immunotherapy.
▶
1:00:42 Sarcoma Exchange 2026: Patient Panel Led by Christina Kosyla
Facilitated by Christina Kosyla of the Cactus Cancer Society, this panel brings together people who have participated in sarcoma clinical trials to share what the experience entailed, and the advice they'd offer anyone considering a trial.
▶
28:04 Sarcoma Exchange 2026: How to Make an Informed Decision with Denise Reinke
Philip Leider of the Sarcoma Alliance and Denise Reinke of the Sarcoma Patient Advocacy Global Network walk through the questions to ask when deciding whether a trial is right for you.
▶
24:09 Sarcoma Exchange 2026: Finding Trials You're Eligible For with Dr. Diego Barrenechea of Massive Bio
Dr. Diego Barrenechea of Massive Bio covers the search tools available to patients — from ClinicalTrials.gov to AI-assisted matching services — and how eligibility criteria work.
▶
22:23 Sarcoma Exchange 2026: Logistics of Enrolling & Participating with Dr. Josep Garcia from INHIBRX
Dr. Josep Garcia of INHIBRX covers the practical side of enrolling and participating — screening and consent, study visits and scheduling, what's expected of participants, and the support available along the way.
▶
13:33 Moleculin CEO on Annamycin Trial Data in AML and Sarcoma
Moleculin CEO Walter Klemp discusses 2023 year-end preliminary data from Annamycin clinical trials in acute myeloid leukemia and soft tissue sarcoma lung metastases.
▶
6:09 Annamycin: A Next-Generation Anthracycline
Moleculin Biotech on Annamycin, a next-generation anthracycline in trials for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.